First Tracks (TRAX) news

First Tracks Biopharmaceuticals Inc: JP Morgan raises target price to $65 from $30

Barclays has raised its price target for First Tracks Biotherapeutics (TRAX) to $65 from $48, maintaining an Overweight rating following the company’s Q2 2026 report . This adjustment reflects the firm’s increased confidence in the company’s development strategy, particularly for ANB033, a CD122…

First Tracks Biopharmaceuticals Inc: Wedbush raises target price to $70 from $60

Wedbush Securities has revised its price target for First Tracks Biotherapeutics Inc (TRAX) to $70 from $60, while maintaining an "Outperform" rating . This adjustment reflects the firm’s updated assessment of the company’s financial outlook and market potential. Currently, the stock has an average…

First Tracks Biopharmaceuticals, Inc.: H.C. Wainwright raises target price to $57 from $44

First Tracks Biopharmaceuticals, Inc. (TRAX) has seen its 12-month price target raised by analysts, reflecting growing optimism about its future performance. According to the latest consensus from eight analysts, the average price target for the company’s stock has increased to $60.50 from $53.25,…

First Tracks Biopharmaceuticals Inc: Wedbush raises target price to $60 from $30

First Tracks Biopharmaceuticals Inc.: Wells Fargo raises target price to $55 from $30